正常人多焦视网膜电图的特征

目的:探讨正常人多焦视网膜电图(multicalelec-troretinogram,mERG)在视网膜的分布特征,以获得正常参考值。方法:应用法国Metrovision公司生产的VisionMonitor视觉诱发系统检测15例(24眼)正常人mERG,检测视野的水平视角±30°,垂直视角±23°,采用ERG-jet接触镜电极,于5min记录61个视网膜部位的反应。结果:黄斑中心凹N1波、P1波、N2波的振幅密度最大,分别为(47.26±19.51)nV/deg2,(118.22±45.08)nV/deg2,(127.55±38.83)nV/deg2,向周边振幅密度逐渐降低;N1波、P1波的颞侧振幅密度较鼻侧大;P1波、N2波的颞上区振幅密度较鼻下区大。黄斑中心凹P1波、N2波的潜伏期均较其他各区缩短。结论:mERG的各波振幅密度与视网膜感光细胞的分布基本一致,能准确、客观的反映视网膜各部位的功能。     

全麻下改良额肌瓣悬吊术治疗儿童先天性重度上睑下垂临床观察

目的寻找一种治疗先天性重度上睑下垂的有效手术方法。方法总结94眼先天性重度上睑下垂行改良额肌瓣悬吊术。结果94眼中85眼满意(90%),94眼基本满意(100%)。结论该术式简单,效果好,是治疗先天性重度上睑下垂的首选方法。     

眼灌注压对人视乳头微循环的影响

目的 了解眼外负压吸引诱导的眼灌注压改变的条件下，正常人、原发性开角性青光眼(POAG)患者和正常眼压性青光眼患者(NTG)的视乳头微循环的变化，探讨视乳头局部自身调节的幅度。方法正常人8例，POAG患者10例和NTG患者7例，采用眼外负压杯吸引诱导眼压升高，负压增加的幅度为30s50mmHg，同时测量眼压。采用HRF测量视乳头处血流量。将基础状态下视乳头血流值作为基础值，当眼压升高到30mmHg和40mmHg时，分别测量这两点视乳头微循环的血流值，在40mmHg后解除负压吸引，测量负压吸引解除后1min、5min时视乳头微循环的血流值。结果 三组视乳头的基础血流量无明显差异。当眼压升高到30mmHg时，正常组的血流量仍维持稳定，但POAG组和NTG组明显下降，POAG组下降幅度超过25％，NTG组下降幅度超过45％。当眼压升高到40mmHg，正常组视乳头血流量也出现明显下降，其中0NHF下降约30％，POAG组和NTG组下降更明显，POAG组下降幅度超过50％，NTG组下降幅度超过65％。在解除负压吸引后1min，正常组血流量增加的幅度约为31％，POAG组增加约19％，NTG组无明显增加。在负压解除后5min，三组视乳头血流基本恢复到基础状态。结论 正常组视乳头微循环有一定范围的自身调节幅度，可以耐受眼灌注压一定程度的改变，POAG组和NTG组自身调节能力均有不同程度的损害。     

纳络酮对缺氧缺血性脑病新生儿血浆神经肽Y和β-内啡肽的影响

目的探讨新生儿缺氧缺血性脑病(HIE)血浆神经肽Y(NPY)、β-内啡肽(β-EP)的变化及纳络酮治疗后对其的影响。方法将34例中、重度HIE患儿随机分成常规治疗组(18例),纳络酮治疗组(16例),以14例正常新生儿为对照组,纳络酮治疗组入院后在常规治疗的基础上给予纳络酮治疗,连用3天。HIE患儿组治疗前、治疗3d后各采血收集标本一次,采用放射免疫法测定NPY、β-EP。结果①HIE患儿血浆NPY、β-EP水平为(174.23±18.31)ng／L、(123.36±16.42)ng／L均显著高于正常对照组(87.19±12.95)ng／L、(63.27±12.65)ng／L(P<0.01)。HIE急性期NPY与β-EP呈正相关(r=0.347,P<0.05)。②HIE常规组、纳络酮组治疗3d后血浆NPY、β-EP水平均较治疗前显著降低(P<0.01)。治疗后HIE纳络酮组NPY、β-EP水平均显著低于常规组(P<0.01)。结论NPY、β-EP共同参与了HIE的病理生理过程,在HIE发病机制中可能起重要作用;纳络酮能显著降低NPY、β-EP水平,减轻脑损伤。     

小儿严重烧伤早期防治休克综合治疗观察

目的探讨小儿严重烧伤早期综合防治休克的治疗效果。方法回顾性分析205例小儿严重烧伤临床资料,按早期是否进行休克综合治疗划分为两组(进行综合防治为Ⅰ组,不进行则为Ⅱ组),并进行比较分析。结果Ⅰ组与Ⅱ组比较,患者年龄、烧伤面积与深度无明显差异(P>0.05),Ⅰ组治愈率明显提高(P<0.01),并发症明显下降(P<0.01)。结论小儿严重烧伤早期防治休克综合治疗明显提高治愈率,减少并发症。     

降低体重指数对原发性高血压病降压效果的影响及其临床意义

目的探讨降低体重指数(BodyMassIndex,BMI)对原发性高血压病降压效果的影响及其临床意义。方法选择40例超重或肥胖的(BMI≥24)原发性高血压病患者,分为治疗组与对照组,降低治疗组患者的体重指数,同时观察两组治疗前后血压的变化。结果发现治疗组患者降低体重指数后血压有明显下降,与对照组相比有显著的临床意义(P<0.05)。结论降低超重或肥胖的高血压病患者的体重指数可起到一定的降压效果,应注意降低患者的体重指数。     

唯物辩证法在医学检验形态学实验教学中的应用与思考

本文探讨了在医学检验形态学实验教学中应用内因与外因、局部与整体、一般与特殊、量变与质变、认识论与方法论等唯物辩证法哲学范畴和观点,融知识传授与哲学思维的培养于一体,不断提高学生的学习兴趣和分析问题、解决问题的能力,同时培养学生的科学辩证思维,使他们学会用科学的态度和方法指导自身的工作、学习,逐步成为具有创新精神和实践能力的高素质应用型检验医学人才.     

RNA干扰及其技术的应用

RNA干扰(RNAi)是细胞内由双链RNA诱导降解与其配对的特定mRNA的过程。细胞内双链RNA在酶的作用下,形成20-25碱基大小的小干扰RNA(si RNAs),由si RNAs进一步掺入多组分核酸酶并使其激活,从而精确降解与si RNAs序列相同的mRNA,抑制该基因在细胞内的翻译表达。介绍了RNA干扰的分子机制、制备方法、以及RNA干扰技术在功能基因组学、微生物学、基因治疗和信号转导等研究领域里的应用。     

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

PURPOSE: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). The regimens were compared with regard to effects on survival, response rates, toxicity, and quality of life. PATIENTS AND METHODS: Eligible patients had previously untreated stage IIIB or IV NSCLC suitable for cisplatin-based chemotherapy. Randomly assigned patients were to receive four cycles, each at 3-week intervals, of carboplatin area under the curve of 5 on day 1 plus gemcitabine 1,200 mg/m(2) on days 1 and 8 (GCa) or mitomycin 6 mg/m(2), ifosfamide 3g/m(2), and cisplatin 50 mg/m(2) on day 1 (MIC). RESULTS: Between February 1999 and August 2001, 422 patients (GCa, n = 212; MIC, n = 210) were randomly assigned in the United Kingdom. The majority of patients received the intended four cycles (GCa, 64%; MIC, 61%). There was a significant survival advantage for GCa compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P = .008). Median survival was 10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0), and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to 18%). Overall response rates were similar (42% for GCa v 41% for MIC; P = .84). More thrombocytopenia occurred with GCa (P = .03), but this was not associated with increased hospital admission or fatality. GCa caused less nausea, vomiting, constipation, and alopecia and was associated with fewer admissions for administration and better quality of life. CONCLUSION: In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated treatment that conferred a survival advantage over MIC.